MeMed raises $70M for immune system-based infection diagnostics

Medicine Money
MeMed plans to use the money to pursue clearance of its point-of-care protein measurement platform. (Getty/utah778)

MeMed has raised over $70 million to support its point-of-care immune system diagnostic for distinguishing between bacterial and viral infections. The company aims to cut down on the misuse of antibiotics, to avoid ineffective treatments and the spread of drug-resistant strains.

In addition, the Haifa, Israel-based company plans to use the money to complete its MeMed Key protein measurement platform, as well as expand its pipeline to include other machine learning- and immune-based tests.

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

"Importantly, the MeMed Key platform opens the way to central lab precision at the point-of-care,” said Kfir Oved, the company’s co-founder and chief technology officer, describing how the Key platform will be able to run MeMed’s infection test within minutes once it is cleared.

“It will allow measurement of multiple other proteins and signatures, both conventional and new, that currently are only measurable in the central lab,” Oved added. “This unlocks enormous value in diagnosing and managing patients across a wide range of other diseases.”

The series C funding round included support from Ping An Global Voyager Fund, Foxconn, Caesarea Medical Holdings, Clal Insurance, Phoenix Insurance, OurCrowd, Social Capital, WTI, Horizons Ventures and others.

“Beyond profoundly benefiting individual patients, this groundbreaking technology will address antibiotic overuse within the broader population and contribute to reducing the growing burden of antibiotic resistance,” said Marco Huesch, chief medical officer of the Ping An Voyager Fund.

One year ago, MeMed presented data from a study of nearly 600 children and adolescents showing the accuracy of its CE-marked blood test for differentiating acute infections. The test measures immune system biomarkers and uses algorithms to recognize patterns linked to viral or bacterial contagions.

The study included patients with respiratory tract infections, urinary tract infections and those with a fever that had no identifiable source. At the time, the test beat out routine laboratory assays commonly used to manage patients with infections, such as white blood cell counts.

Suggested Articles

NYC’s outstanding talent and funding, the city is rich with life science real estate offerings across the five boroughs.

Everlywell’s sales of at-home diagnostic tests, including one kit for COVID-19, are projected to quadruple this year—and investors have taken notice.

Sutro Biopharma’s lead antibody-drug conjugate shrank tumors in 13% of patients with ovarian cancer who had tried a median of six other treatments.